Normal view MARC view ISBD view

Prevention and treatment of thrombosis associated with central venous catheters in cancer patients. [Review]

MedStar author(s):

Citation: Expert Rev Hematol. 7(5):599-616, 2014 Oct.Expert Review of Hematology. 7(5):599-616, 2014 Oct.PMID: 25174434Institution: MedStar Harbor HospitalDepartment: Internal MedicineForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Anticoagulants/tu [Therapeutic Use] | *Neoplasms/co [Complications] | *Thrombosis/dt [Drug Therapy] | Central Venous Catheters | Clinical Trials as Topic | Humans | Risk Factors | Thrombosis/co [Complications] | Thrombosis/pc [Prevention & Control]Year: 2014 ISSN:

1747-4094

Name of journal: Expert review of hematologyAbstract: Central venous catheters (CVC) play an essential role in the management of cancer patients. Venous thrombosis is a common complication of CVC. The incidence of CVC-associated venous thromboembolism (CVC-VTE) is 1.7 per 1000 catheter days. Risk factors for CVC-VTE include the patient's underlying cancer, a history of previous thrombotic events and the location and type of CVC. Anticoagulant prophylaxis is not effective for CVC-VTE. Anticoagulation alone is the preferred initial treatment for CVC-VTE. CVC removal may be considered in refractory cases or when anticoagulation is contraindicated. Thrombolytic therapy is reserved for patients with limb-threatening thrombosis or thrombosis unresponsive to conventional treatment. Anticoagulation should be continued for at least 3 months or as long as the CVC is present.All authors: Jasti N, Streiff MBFiscal year: FY2015Digital Object Identifier:

http://dx.doi.org/10.1586/17474086.2014.954541

Date added to catalog: 2016-07-15

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	25174434	Available		25174434

Central venous catheters (CVC) play an essential role in the management of cancer patients. Venous thrombosis is a common complication of CVC. The incidence of CVC-associated venous thromboembolism (CVC-VTE) is 1.7 per 1000 catheter days. Risk factors for CVC-VTE include the patient's underlying cancer, a history of previous thrombotic events and the location and type of CVC. Anticoagulant prophylaxis is not effective for CVC-VTE. Anticoagulation alone is the preferred initial treatment for CVC-VTE. CVC removal may be considered in refractory cases or when anticoagulation is contraindicated. Thrombolytic therapy is reserved for patients with limb-threatening thrombosis or thrombosis unresponsive to conventional treatment. Anticoagulation should be continued for at least 3 months or as long as the CVC is present.

English